Phenotypes Associated with This Genotype

Genotype
MGI:5911329

• Allelic Composition: Med1^tm2Jkr/Med1^tm2Jkr; A1cf^{Tg(Myh6-cre/Esr1*)1Jmk}/A1cf⁺
• Genetic Background: involves: 129P2/OlaHsd * FVB/N

• ♀: phenotype observed in females
• ♂: phenotype observed in males
• N: normal phenotype

The Med1^tm2Jkr/Med1^tm2Jkr A1cf^{Tg(Myh6-cre/Esr1*)1Jmk}/A1cf⁺ mouse heart is flaccid and flabby after tamoxifen induction.

mortality/aging

premature death ( J:243730 )

• mice survive between 13 and 28 days after the first day of tamoxifen injection

cardiovascular system

abnormal heart morphology ( J:243730 )

• hearts appear increasingly flaccid by 14 days after first tamoxifen injection

enlarged heart ( J:243730 )

• mice treated with tamoxifen at 7 weeks of age exhibit an increase in heart size by 14 days after first tamoxifen injection

thin ventricular wall ( J:243730 )

• tamoxifen treated mice show thinning of the ventricular walls

dilated heart ventricle ( J:243730 )

• tamoxifen treated mice show dilatation of the right and left ventricular chambers with thinning of the walls and myocardial cells

cardiac interstitial fibrosis ( J:243730 )

• interstitial myocardial fibrosis in tamoxifen-treated hearts

dilated cardiomyopathy ( J:243730 )

decreased cardiac muscle contractility ( J:243730 )

• tamoxifen-treated mice show diminished heart contractility with ejection fraction only 11% vs. 64% in controls and fractional shortening of 4.77% vs. 33.88% in controls

abnormal heart echocardiography feature ( J:243730 )

• echocardiography indicates increased left ventricular end-diastolic internal dimension, and decreased fractional shortening and ejection fraction in tamoxifen treated mice

congestive heart failure ( J:243730 )

• in tamoxifen treated mice

cellular

cardiac interstitial fibrosis ( J:243730 )

• interstitial myocardial fibrosis in tamoxifen-treated hearts

increased cardiomyocyte apoptosis ( J:243730 )

• tamoxifen-treated hearts show enhanced apoptosis, with the number of apoptotic cardiomyocytes increased about 10-fold

muscle

dilated cardiomyopathy ( J:243730 )

decreased cardiac muscle contractility ( J:243730 )

• tamoxifen-treated mice show diminished heart contractility with ejection fraction only 11% vs. 64% in controls and fractional shortening of 4.77% vs. 33.88% in controls

increased cardiomyocyte apoptosis ( J:243730 )

• tamoxifen-treated hearts show enhanced apoptosis, with the number of apoptotic cardiomyocytes increased about 10-fold

growth/size/body

enlarged heart ( J:243730 )

• mice treated with tamoxifen at 7 weeks of age exhibit an increase in heart size by 14 days after first tamoxifen injection

Mouse Models of Human Disease		DO ID	OMIM ID(s)	Ref(s)
congestive heart failure		DOID:6000		J:243730
dilated cardiomyopathy		DOID:12930	OMIM:PS115200	J:243730